ORBIMED ADVISORS LLC bought QTTB

May 28, 2026 · Form 4 insider transaction

ORBIMED ADVISORS LLC bought 1,250,000 shares of Q32 Bio Inc. at $8.00 per share, a transaction worth $10.00M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 4 days after the transaction.

Direction
Acquired (buy-side)
Shares
1,250,000
Price
$8.00
Total value
$10.00M
Role
SecurityCommon Stock
Transaction codeP: Open-market purchase
Transaction dateMay 28, 2026
Filing dateJune 1, 2026
Shares owned after3,502,987
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

These shares of the Issuer's common stock were purchased from the Issuer in a private placement.; These securities are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII.; This report on Form 4 is jointly filed by OrbiMed Advisors, OrbiMed GP, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Diyong Xu, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

View the original Form 4 on SEC EDGAR